Search

Displaying results 1991 - 2000 of 4859 in total
  1. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    [L51114] On August 2, 2024, the FDA granted the accelerated approval of afamitresgene autoleucel, making it the first FDA-approved TCR gene therapy and the first gene therapy for the treatment of synovial

  2. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis.

  3. Drug

    Cefditoren

    go.drugbank.com/drugs/DB01066
    Approved

    It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.

  4. Drug

    Zofenopril

    go.drugbank.com/drugs/DB13166
    ApprovedInvestigational

    It is an angiotensin-converting enzyme (ACE) inhibitor.

  5. Drug

    Tranexamic acid

    go.drugbank.com/drugs/DB00302
    ApprovedInvestigational

    [L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858] … It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.

  6. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.

  7. Drug

    Suramin

    go.drugbank.com/drugs/DB04786
    Investigational

    It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. … (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. Suramin is manufactured by Bayer in Germany as Germanin®.

  8. Drug

    Loteprednol etabonate

    go.drugbank.com/drugs/DB14596
    Approved

    As a nasal spray, it can be used for the treatment and management of seasonal allergic rhinitis. … It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes

  9. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924].

  10. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940] By preventing this aberrant signaling, it reduces the formation of new abnormal bone.[L63940] It is administered by intravenous infusion every four weeks. … [L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic